(Q35173077)

6 August 2017

1 reference

title

Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers (English)

1 reference

6 August 2017

1 reference

Cora N Sternberg

1

1 reference

PubMed ID

12850531

6 August 2017

Nicholas J Vogelzang

series ordinal

2

1 reference

PubMed ID

12850531

6 August 2017

language of work or name

1 reference

1 June 2003

1 reference

Critical Reviews in Oncology Hematology

6 August 2017

1 reference

6 August 2017

46 Suppl

1 reference

6 August 2017

S105-15

1 reference

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Future directions for gemcitabine in the treatment of genitourinary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Novel gemcitabine-containing triplets in the management of urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Gemcitabine doublets in advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Overview of gemcitabine triplets in metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Folate status and the safety profile of antifolates

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nerv

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Farnesyl transferase inhibitors--a novel therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

The ErbB receptor family: a therapeutic target for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Gemcitabine: a phase II study in patients with advanced renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Thalidomide in solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Novel therapies for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

The treatment of advanced renal cell cancer with high-dose oral thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

High-dose toremifene in advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Sex hormones and renal neoplasia.Inhibition of tumor of hamster kidney by an estrogen antagonist, an agent of possible therapeutic value in man

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Sensitivity of renal cell cancer to nonmyeloablative allogeneic hematopoietic cell transplantations: unusual or unusually important?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900068-4

7 January 2021

10.1016/S1040-8428(03)00068-4

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b5u2yo36rbbm7bapexjnmw73oi

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_b5u2yo36rbbm7bapexjnmw73oi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b5u2yo36rbbm7bapexjnmw73oi

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/b5u2yo36rbbm7bapexjnmw73oi

30 July 2022